Literature DB >> 10630505

Expression of syndecan-1 in inflammatory bowel disease and a possible mechanism of heparin therapy.

R Day1, M Ilyas, P Daszak, I Talbot, A Forbes.   

Abstract

Heparin apparently aids healing in ulcerative colitis although its mechanism of action is unknown. The purpose of this study was to investigate the hypothesis that heparin functions as a coreceptor molecule for basic fibroblast growth factor, a role usually performed by heparan sulfate chains on syndecan-1. A marked reduction of syndecan-1 immunostaining was found in reparative epithelium from inflammatory bowel disease patients. Removal of heparan sulfate on gastrointestinal epithelial cells in vitro reduced the proliferative response to basic fibroblast growth factor. The response to basic fibroblast growth factor was completely restored by the addition of heparin. Loss of syndecan-1 expression occurs in the regenerative mucosa in inflammatory bowel disease. Although this may facilitate tissue motility, its loss probably adversely affects the ability of cells to bind basic fibroblast growth factor. The present data show that heparin may substitute the loss of functional activity of syndecan-1 in the binding of basic fibroblast growth factor.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630505     DOI: 10.1023/a:1026647308089

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

Review 1.  Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans.

Authors:  M Bernfield; R Kokenyesi; M Kato; M T Hinkes; J Spring; R L Gallo; E J Lose
Journal:  Annu Rev Cell Biol       Date:  1992

2.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation.

Authors:  A C Rapraeger; A Krufka; B B Olwin
Journal:  Science       Date:  1991-06-21       Impact factor: 47.728

3.  Downregulation of E-cadherin in the reparative epithelium of the human gastrointestinal tract.

Authors:  A M Hanby; R Chinery; R Poulsom; R J Playford; M Pignatelli
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

Review 4.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

5.  Immunocytochemistry of cell surface heparan sulfate proteoglycan in mouse tissues. A light and electron microscopic study.

Authors:  K Hayashi; M Hayashi; M Jalkanen; J H Firestone; R L Trelstad; M Bernfield
Journal:  J Histochem Cytochem       Date:  1987-10       Impact factor: 2.479

6.  A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1.

Authors:  J Wijdenes; W C Vooijs; C Clément; J Post; F Morard; N Vita; P Laurent; R X Sun; B Klein; J M Dore
Journal:  Br J Haematol       Date:  1996-08       Impact factor: 6.998

7.  Effect of growth factors on cell proliferation and epithelialization in human skin.

Authors:  F Y Bhora; B J Dunkin; S Batzri; H M Aly; B L Bass; A N Sidawy; J W Harmon
Journal:  J Surg Res       Date:  1995-08       Impact factor: 2.192

8.  Immunocytochemical localization of basic fibroblast growth factor in carcinomas and inflammatory lesions of the human digestive tract.

Authors:  H Ohtani; S Nakamura; Y Watanabe; T Mizoi; T Saku; H Nagura
Journal:  Lab Invest       Date:  1993-05       Impact factor: 5.662

9.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor.

Authors:  A Yayon; M Klagsbrun; J D Esko; P Leder; D M Ornitz
Journal:  Cell       Date:  1991-02-22       Impact factor: 41.582

10.  Paradoxical response to heparin in 10 patients with ulcerative colitis.

Authors:  P R Gaffney; C T Doyle; A Gaffney; J Hogan; D P Hayes; P Annis
Journal:  Am J Gastroenterol       Date:  1995-02       Impact factor: 10.864

View more
  18 in total

1.  Heparan sulfate proteoglycans mediate Staphylococcus aureus interactions with intestinal epithelium.

Authors:  Donavon J Hess; Michelle J Henry-Stanley; Stanley L Erlandsen; Carol L Wells
Journal:  Med Microbiol Immunol       Date:  2005-12-24       Impact factor: 3.402

Review 2.  Fibrogenesis and fibrosis in inflammatory bowel diseases: Good and bad side of same coin?

Authors:  Mariabeatrice Principi; Floriana Giorgio; Giuseppe Losurdo; Viviana Neve; Antonella Contaldo; Alfredo Di Leo; Enzo Ierardi
Journal:  World J Gastrointest Pathophysiol       Date:  2013-11-15

3.  Reduced heparan sulfate accumulation in enterocytes contributes to protein-losing enteropathy in a congenital disorder of glycosylation.

Authors:  V Westphal; S Murch; S Kim; G Srikrishna; B Winchester; R Day; H H Freeze
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.

Authors:  I Dotan; A Hallak; N Arber; M Santo; A Alexandrowitz; Y Knaani; R Hershkoviz; E Brazowski; Z Halpern
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

5.  Heparan sulfate on intestinal epithelial cells plays a critical role in intestinal crypt homeostasis via Wnt/β-catenin signaling.

Authors:  Shuji Yamamoto; Hiroshi Nakase; Minoru Matsuura; Yusuke Honzawa; Kayoko Matsumura; Norimitsu Uza; Yu Yamaguchi; Emiko Mizoguchi; Tsutomu Chiba
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-06-06       Impact factor: 4.052

6.  Soluble Syndecan-1 Levels Are Elevated in Patients with Inflammatory Bowel Disease.

Authors:  Doron Yablecovitch; Assaf Stein; Maytal Shabat-Simon; Timna Naftali; Gila Gabay; Ido Laish; Asaf Oren; Fred M Konikoff
Journal:  Dig Dis Sci       Date:  2015-02-22       Impact factor: 3.199

7.  Enoxaparin improves the course of dextran sodium sulfate-induced colitis in syndecan-1-deficient mice.

Authors:  Martin Floer; Martin Götte; Martin K Wild; Jan Heidemann; Ezeddin Salem Gassar; Wolfram Domschke; Ludwig Kiesel; Andreas Luegering; Torsten Kucharzik
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

Review 8.  Versatile role of heparanase in inflammation.

Authors:  Rachel Goldberg; Amichay Meirovitz; Nir Hirshoren; Raanan Bulvik; Adi Binder; Ariel M Rubinstein; Michael Elkin
Journal:  Matrix Biol       Date:  2013-03-13       Impact factor: 11.583

Review 9.  Heparanase in inflammation and inflammation-associated cancer.

Authors:  Amichay Meirovitz; Rachel Goldberg; Adi Binder; Ariel M Rubinstein; Esther Hermano; Michael Elkin
Journal:  FEBS J       Date:  2013-03-04       Impact factor: 5.542

Review 10.  Heparanase enzyme in chronic inflammatory bowel disease and colon cancer.

Authors:  Esther Hermano; Immanuel Lerner; Michael Elkin
Journal:  Cell Mol Life Sci       Date:  2012-02-14       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.